thioctic acid has been researched along with Blood Pressure, High in 32 studies
Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigated possible mechanisms for cardioprotective effects of lipoic acid (LA), quercetin (Q) and resveratrol (R) on oxidative stress related to thyroid hormone alterations in long-term obesity." | 7.83 | Cardioprotective effects of lipoic acid, quercetin and resveratrol on oxidative stress related to thyroid hormone alterations in long-term obesity. ( Cheserek, MJ; Karangwa, E; Le, G; Li, L; Shi, Y; Wu, G, 2016) |
| "This study investigated possible mechanisms for cardioprotective effects of lipoic acid (LA), quercetin (Q) and resveratrol (R) on oxidative stress related to thyroid hormone alterations in long-term obesity." | 3.83 | Cardioprotective effects of lipoic acid, quercetin and resveratrol on oxidative stress related to thyroid hormone alterations in long-term obesity. ( Cheserek, MJ; Karangwa, E; Le, G; Li, L; Shi, Y; Wu, G, 2016) |
| "Hypertension was induced in Sprague-Dawley rats by infusing angiotensin II (200 ng/kg per min) through osmotic pumps for 12 days." | 3.72 | NAD(P)H oxidase activation by angiotensin II is dependent on p42/44 ERK-MAPK pathway activation in rat's vascular smooth muscle cells. ( de Champlain, J; El Midaoui, A; Laplante, MA; Wu, R, 2003) |
| "This is a prospective parallel, randomized, double-blind, placebo-controlled trial to study the effects of α lipoic acid in combination with olmesartan medoxomil on blood glucose and oxidation indicators in patients with DN." | 3.11 | Effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with diabetic nephropathy: A protocol for a parallel, randomized, double-blind, controlled clinical trial. ( Chang, X; Dong, Y; Jiao, S; Li, H; Wu, Y, 2022) |
| " Therefore, the results of valsartan and amlodipine tablets combined with alpha-lipoic acid on total antioxidant capacity (T-AOC) need to be investigated." | 1.91 | Effects of Valsartan and Amlodipine Tablets Combined with α-Lipoic Acid on T-AOC, IL-6 and β2-MG Levels in Patients with Diabetic Nephropathy. ( Su, F; Xia, Q, 2023) |
| "Arterial hypertension is accompanied by an increased oxidative stress status in the heart characterized by thiobarbituric acid reactive substances (TBARS) and nucleic acid oxidation increase." | 1.43 | Effect of treatment with the antioxidant alpha-lipoic (thioctic) acid on heart and kidney microvasculature in spontaneously hypertensive rats. ( Amenta, F; Di Cesare Mannelli, L; Tayebati, SK; Tomassoni, D, 2016) |
| "Alpha-lipoic acid at a dosage of 50 mg/kg b." | 1.43 | Hypotensive effect of alpha-lipoic acid after a single administration in rats. ( Bilska-Wilkosz, A; Dudek, M; Filipek, B; Iciek, M; Razny, K; Sapa, J; Wlodek, L, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (50.00) | 29.6817 |
| 2010's | 14 (43.75) | 24.3611 |
| 2020's | 2 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Jiao, S | 1 |
| Dong, Y | 1 |
| Chang, X | 1 |
| Wu, Y | 1 |
| Li, H | 1 |
| Su, F | 1 |
| Xia, Q | 1 |
| Ong, SL | 1 |
| Vohra, H | 1 |
| Zhang, Y | 1 |
| Sutton, M | 1 |
| Whitworth, JA | 1 |
| Ergür, BU | 2 |
| Çilaker Mıcılı, S | 1 |
| Yılmaz, O | 1 |
| Akokay, P | 1 |
| Mendes, PR | 1 |
| Félix, Ddos S | 1 |
| Silva, PC | 1 |
| Pereira, GH | 1 |
| Simões, MO | 1 |
| Tayebati, SK | 1 |
| Tomassoni, D | 1 |
| Di Cesare Mannelli, L | 1 |
| Amenta, F | 1 |
| de Queiroz, TM | 1 |
| Xia, H | 1 |
| Filipeanu, CM | 1 |
| Braga, VA | 1 |
| Lazartigues, E | 1 |
| Dudek, M | 1 |
| Razny, K | 1 |
| Bilska-Wilkosz, A | 1 |
| Iciek, M | 1 |
| Sapa, J | 1 |
| Wlodek, L | 1 |
| Filipek, B | 1 |
| Su, Q | 1 |
| Liu, JJ | 1 |
| Cui, W | 1 |
| Shi, XL | 1 |
| Guo, J | 1 |
| Li, HB | 1 |
| Huo, CJ | 1 |
| Miao, YW | 1 |
| Zhang, M | 1 |
| Yang, Q | 1 |
| Kang, YM | 1 |
| Cheserek, MJ | 1 |
| Wu, G | 1 |
| Li, L | 2 |
| Karangwa, E | 1 |
| Shi, Y | 1 |
| Le, G | 1 |
| Gao, S | 1 |
| Park, BM | 1 |
| Cha, SA | 1 |
| Bae, UJ | 1 |
| Park, BH | 1 |
| Park, WH | 1 |
| Kim, SH | 1 |
| Huang, YP | 1 |
| Jin, HY | 1 |
| Yu, HP | 1 |
| Hatzitolios, A | 1 |
| Iliadis, F | 1 |
| Katsiki, N | 1 |
| Baltatzi, M | 1 |
| Shay, KP | 1 |
| Moreau, RF | 1 |
| Smith, EJ | 1 |
| Smith, AR | 1 |
| Hagen, TM | 1 |
| Rahman, ST | 1 |
| Merchant, N | 1 |
| Haque, T | 1 |
| Wahi, J | 1 |
| Bhaheetharan, S | 1 |
| Ferdinand, KC | 1 |
| Khan, BV | 1 |
| Navarro-Sastre, A | 1 |
| Tort, F | 1 |
| Stehling, O | 1 |
| Uzarska, MA | 1 |
| Arranz, JA | 1 |
| Del Toro, M | 1 |
| Labayru, MT | 1 |
| Landa, J | 1 |
| Font, A | 1 |
| Garcia-Villoria, J | 1 |
| Merinero, B | 1 |
| Ugarte, M | 1 |
| Gutierrez-Solana, LG | 1 |
| Campistol, J | 1 |
| Garcia-Cazorla, A | 1 |
| Vaquerizo, J | 1 |
| Riudor, E | 1 |
| Briones, P | 1 |
| Elpeleg, O | 1 |
| Ribes, A | 1 |
| Lill, R | 1 |
| Mıcılı, SC | 1 |
| Ozoğul, C | 1 |
| Sarıoğlu, S | 1 |
| Bağrıyanık, HA | 1 |
| Tuğyan, K | 1 |
| Pekcetin, C | 1 |
| Sonmez, U | 1 |
| Tekmen, I | 1 |
| Erbil, G | 1 |
| Akdoğan, GG | 1 |
| Ozyurt, D | 1 |
| Buldan, Z | 1 |
| Midaoui, AE | 1 |
| Elimadi, A | 1 |
| Wu, L | 2 |
| Haddad, PS | 1 |
| de Champlain, J | 4 |
| Laplante, MA | 1 |
| Wu, R | 1 |
| El Midaoui, A | 3 |
| Vasdev, S | 4 |
| Gill, V | 2 |
| Longerich, L | 3 |
| Parai, S | 4 |
| Gadag, V | 4 |
| Thirunavukkarasu, V | 1 |
| Anitha Nandhini, AT | 1 |
| Anuradha, CV | 1 |
| Ross, CM | 1 |
| Wang, R | 1 |
| Louhelainen, M | 1 |
| Merasto, S | 1 |
| Finckenberg, P | 1 |
| Lapatto, R | 1 |
| Cheng, ZJ | 1 |
| Mervaala, EM | 1 |
| Hadj, A | 1 |
| Pepe, S | 1 |
| Rosenfeldt, F | 1 |
| Ford, CA | 2 |
| Takaoka, M | 1 |
| Kobayashi, Y | 1 |
| Yuba, M | 1 |
| Ohkita, M | 1 |
| Matsumura, Y | 1 |
| Chukanova, EI | 1 |
| Sokolova, NA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Biological Characteristics of Adipose Tissue-derived Mesenchymal Stem Cells and Its Role in the Treatment of Chronic Renal Failure[NCT03321942] | 100 participants (Anticipated) | Interventional | 2017-01-01 | Recruiting | |||
| Effects of the Supplementation of α-lipoic Acid (ALA), Magnesium, Vitamin B6 and Vitamin D to Women Presenting Risk Factor for Pre-term Birth[NCT03952533] | 122 participants (Actual) | Interventional | 2019-05-05 | Completed | |||
| Exploratory Study of Lipoic Acid Supplementation on Oxidative Stress, Inflammatory and Functional Markers in Asthmatic Patients: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial.[NCT01221350] | 55 participants (Actual) | Interventional | 2010-11-30 | Completed | |||
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Proteins can become modified by a large number of reactions involving reactive oxygen species. Among these, carbonylation is an irreversible and unrepairable oxidative reaction. The main protein modifications originated from oxidative stress comprise direct oxidation of aminoacids with a thiol group, such as cysteine, oxidative glycation, and carbonylation. Oxidative protein carbonylation induce protein degradation in a nonspecific manner. Chemically, oxidative carbonylation preferentially occurs at proline, threonine, lysine, and arginine, presumably through a metal-catalyzed activation of hydrogen peroxide to a reactive intermediate. Carbonylation usually refers to a process that forms reactive ketones or aldehydes that can be reacted by 2,4-dinitrophenylhydrazine (DNPH) to form hydrazones. Direct oxidation of side chains of lysine, arginine, proline, and threonine residues, among other aminoacids, produces DNPH detectable protein products (NCT01221350)
Timeframe: Baseline
| Intervention | nmol/mg (Mean) |
|---|---|
| Lipoic Acid | 7.5 |
| Placebo | 10.12 |
Proteins can become modified by a large number of reactions involving reactive oxygen species. Among these, carbonylation is an irreversible and unrepairable oxidative reaction. The main protein modifications originated from oxidative stress comprise direct oxidation of aminoacids with a thiol group, such as cysteine, oxidative glycation, and carbonylation. Oxidative protein carbonylation induce protein degradation in a nonspecific manner. Chemically, oxidative carbonylation preferentially occurs at proline, threonine, lysine, and arginine, presumably through a metal-catalyzed activation of hydrogen peroxide to a reactive intermediate. Carbonylation usually refers to a process that forms reactive ketones or aldehydes that can be reacted by 2,4-dinitrophenylhydrazine (DNPH) to form hydrazones. Direct oxidation of side chains of lysine, arginine, proline, and threonine residues, among other aminoacids, produces DNPH detectable protein products. (NCT01221350)
Timeframe: 60 days
| Intervention | nmol/mg (Mean) |
|---|---|
| Lipoic Acid | 3.24 |
| Placebo | 4.21 |
Eosinophils, a prominent feature of asthma, are found in increased numbers in the circulation and sputum, usually in relation to the severity of asthma. (NCT01221350)
Timeframe: Baseline
| Intervention | Eosinophil percentage in sputum cells (Mean) |
|---|---|
| Lipoic Acid | 12.88 |
| Placebo | 6.10 |
Eosinophils, a prominent feature of asthma, are found in increased numbers in the circulation and sputum, usually in relation to the severity of asthma. (NCT01221350)
Timeframe: 60 days
| Intervention | Eosinophil percentage in sputum cells (Mean) |
|---|---|
| Lipoic Acid | 6.39 |
| Placebo | 5.68 |
Induced sputum of GSH and GSSG levels at baseline. The ratio GSH/GSSG is considered an index of antioxidant status and reductive -SH groups. GSH and GSSG were measured by a microplate fluorescent assay. (NCT01221350)
Timeframe: Baseline
| Intervention | ratio (Mean) |
|---|---|
| Lipoic Acid | 81.42 |
| Placebo | 35.77 |
Change in the induced sputum of antioxidant parameters GSH and GSSG levels after 60 days of treatment. The ratio GSH/GSSG is considered an index of antioxidant status and reductive -SH groups. GSH and GSSG were measured by a microplate fluorescent assay. (NCT01221350)
Timeframe: 60 days
| Intervention | ratio (Mean) |
|---|---|
| Lipoic Acid | 58.6 |
| Placebo | 37.5 |
Inflammatory IL-4 sputum levels after 60 days of treatment. Sputum induction is a semi-invasive technique used to detect and monitor airway inflammation. IL-4 is a Th2 cytokine that promote airway inflammation in asthma. IL-4 drives the production of IgE in B cells. IL-4 was measured by ELISA. (NCT01221350)
Timeframe: 60 days
| Intervention | pg/mL (Mean) |
|---|---|
| Lipoic Acid | 14.53 |
| Placebo | 23.19 |
Inflammatory IL-4 sputum levels after 60 days of treatment. Sputum induction is a semi-invasive technique used to detect and monitor airway inflammation. IL-4 is a Th2 cytokine that promote airway inflammation in asthma. IL-4 drives the production of immunoglobulin E (IgE) in B cells. IL-4 was measured by ELISA. (NCT01221350)
Timeframe: Baseline
| Intervention | pg/mL (Mean) |
|---|---|
| Lipoic Acid | 37.77 |
| Placebo | 39.90 |
Assessment of Quality of life scores with the ACT (Asthma Control Test). The ACT is a way to determine if the asthma symptoms are well controlled. The Asthma Control Test™ (ACT™) is a five question health survey used to measure asthma control in individuals 12 years of age and older. The survey measures the elements of asthma control as defined by the National Heart, Lung, and Blood Institute (NHLBI). ACT is an efficient, reliable, and valid method of measuring asthma control, with or without, lung functioning measures such as spirometry. Each item includes 5 response options corresponding to a 5-point Likert-type rating scale. In scoring the ACT survey, responses for each of the 5 items are summed to yield a score ranging from 5 (poor control of asthma) to 25 (complete control of asthma). (NCT01221350)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Lipoic Acid | 13.65 |
| Placebo | 14.46 |
Assessment of Quality of life scores with the ACT (Asthma Control Test). The ACT is a way to determine if the asthma symptoms are well controlled. The Asthma Control Test™ (ACT™) is a five question health survey used to measure asthma control in individuals 12 years of age and older. The survey measures the elements of asthma control as defined by the National Heart, Lung, and Blood Institute (NHLBI). ACT is an efficient, reliable, and valid method of measuring asthma control, with or without, lung functioning measures such as spirometry. Each item includes 5 response options corresponding to a 5-point Likert-type rating scale. In scoring the ACT survey, responses for each of the 5 items are summed to yield a score ranging from 5 (poor control of asthma) to 25 (complete control of asthma). (NCT01221350)
Timeframe: 60 days
| Intervention | units on a scale (Mean) |
|---|---|
| Lipoic Acid | 19.13 |
| Placebo | 17.71 |
"The Asthma Quality of Life Questionnaire (AQLQ) was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma.~There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). The activity domain contains 5 'patient-specific' questions. This allows patients to select 5 activities in which they are most limited and these activities will be assessed at each follow-up. Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains (http://www.qoltech.co.uk/aqlq.html)." (NCT01221350)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Lipoic Acid | 3.86 |
| Placebo | 3.72 |
"The Asthma Quality of Life Questionnaire (AQLQ) was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma.~There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). The activity domain contains 5 'patient-specific' questions. This allows patients to select 5 activities in which they are most limited and these activities will be assessed at each follow-up. Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains (http://www.qoltech.co.uk/aqlq.html)." (NCT01221350)
Timeframe: 60 days
| Intervention | units on a scale (Mean) |
|---|---|
| Lipoic Acid | 5.57 |
| Placebo | 5.10 |
Measurement of spirometric parameters at baseline: Forced expiratory flow (FEF) is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. (NCT01221350)
Timeframe: Baseline
| Intervention | Liters/sec (Mean) |
|---|---|
| Lipoic Acid | 4.89 |
| Placebo | 6.09 |
Measurement of spirometric FEF after 60 days of treatment: Forced expiratory flow (FEF) is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. (NCT01221350)
Timeframe: 60 days
| Intervention | Liters/sec (Mean) |
|---|---|
| Lipoic Acid | 5.47 |
| Placebo | 6.10 |
Measurement of spirometric predicted parameters at baseline: Forced expiratory volume in 1 second (FEV1), volume that has been exhaled at the end of the first second of forced expiration. (NCT01221350)
Timeframe: Baseline
| Intervention | Liters (Mean) |
|---|---|
| Lipoic Acid | 2.01 |
| Placebo | 2.37 |
Measurement of spirometric predicted parameters after 60 days of treatment. Forced expiratory volume in 1 second (FEV1), volume that has been exhaled at the end of the first second of forced expiration. (NCT01221350)
Timeframe: 60 days
| Intervention | Liters (Mean) |
|---|---|
| Lipoic Acid | 2.26 |
| Placebo | 2.35 |
Measurement of spirometric predicted parameters at baseline. Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration, measured in liters. (NCT01221350)
Timeframe: Baseline
| Intervention | Liters (Mean) |
|---|---|
| Lipoic Acid | 2.74 |
| Placebo | 3.07 |
Measurement of spirometric predicted parameters at the baseline and after 60 days of treatment: Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration, measured in liters. (NCT01221350)
Timeframe: 60 days
| Intervention | Liters (Mean) |
|---|---|
| Lipoic Acid | 2.82 |
| Placebo | 3.06 |
3 reviews available for thioctic acid and Blood Pressure, High
| Article | Year |
|---|---|
Is the anti-hypertensive effect of dietary supplements via aldehydes reduction evidence based? A systematic review.
Topics: Aldehydes; Animals; Ascorbic Acid; Dietary Supplements; Evidence-Based Medicine; Glucose Intolerance | 2008 |
Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.
Topics: Animals; Diabetic Neuropathies; Dietary Supplements; Humans; Hypertension; Inflammation; Models, Bio | 2009 |
Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.
Topics: Animals; Diabetic Neuropathies; Dietary Supplements; Humans; Hypertension; Inflammation; Models, Bio | 2009 |
Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.
Topics: Animals; Diabetic Neuropathies; Dietary Supplements; Humans; Hypertension; Inflammation; Models, Bio | 2009 |
Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.
Topics: Animals; Diabetic Neuropathies; Dietary Supplements; Humans; Hypertension; Inflammation; Models, Bio | 2009 |
Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.
Topics: Animals; Diabetic Neuropathies; Dietary Supplements; Humans; Hypertension; Inflammation; Models, Bio | 2009 |
Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.
Topics: Animals; Diabetic Neuropathies; Dietary Supplements; Humans; Hypertension; Inflammation; Models, Bio | 2009 |
Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.
Topics: Animals; Diabetic Neuropathies; Dietary Supplements; Humans; Hypertension; Inflammation; Models, Bio | 2009 |
Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.
Topics: Animals; Diabetic Neuropathies; Dietary Supplements; Humans; Hypertension; Inflammation; Models, Bio | 2009 |
Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.
Topics: Animals; Diabetic Neuropathies; Dietary Supplements; Humans; Hypertension; Inflammation; Models, Bio | 2009 |
The clinical application of metabolic therapy for cardiovascular disease.
Topics: Adaptation, Physiological; Cardiovascular Diseases; Coenzymes; Exercise; Glucose; Heart Failure; Hum | 2007 |
5 trials available for thioctic acid and Blood Pressure, High
| Article | Year |
|---|---|
Effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with diabetic nephropathy: A protocol for a parallel, randomized, double-blind, controlled clinical trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Glucose; Blood Pressure; Dia | 2022 |
[Correction of endothelial dysfunction in patients with essential hypertension and type 2 diabetes].
Topics: Adult; Blood Glucose; Carotid Arteries; Carotid Intima-Media Thickness; Diabetes Complications; Diab | 2014 |
Effect of alpha lipoic acid on the blood cell count and iron kinetics in hypertensive patients.
Topics: Aged; Anemia; Antioxidants; Blood Cell Count; Double-Blind Method; Female; Humans; Hypertension; Iro | 2014 |
The impact of lipoic acid on endothelial function and proteinuria in quinapril-treated diabetic patients with stage I hypertension: results from the QUALITY study.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cross-Over Studies; Di | 2012 |
[Efficiency of thioctacid in dyscirculatory encephalopathy].
Topics: Aged; Brain; Cerebrovascular Circulation; Cognition Disorders; Diabetes Complications; Female; Human | 2001 |
24 other studies available for thioctic acid and Blood Pressure, High
| Article | Year |
|---|---|
Effects of Valsartan and Amlodipine Tablets Combined with α-Lipoic Acid on T-AOC, IL-6 and β2-MG Levels in Patients with Diabetic Nephropathy.
Topics: Amlodipine; Antihypertensive Agents; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2023 |
The effect of alpha-lipoic acid on mitochondrial superoxide and glucocorticoid-induced hypertension.
Topics: Adrenocorticotropic Hormone; Animals; Antioxidants; Blood Pressure; Dexamethasone; F2-Isoprostanes; | 2013 |
The effects of α-lipoic acid on aortic injury and hypertension in the rat remnant kidney (5/6 nephrectomy) model.
Topics: Administration, Oral; Animals; Antioxidants; Aorta, Abdominal; Blood Pressure; Dietary Supplements; | 2015 |
Effect of treatment with the antioxidant alpha-lipoic (thioctic) acid on heart and kidney microvasculature in spontaneously hypertensive rats.
Topics: Animals; Antioxidants; Coronary Vessels; Endothelial Cells; Endothelium, Vascular; Hypertension; Int | 2016 |
α-Lipoic acid reduces neurogenic hypertension by blunting oxidative stress-mediated increase in ADAM17.
Topics: ADAM Proteins; ADAM17 Protein; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Antioxidant | 2015 |
Hypotensive effect of alpha-lipoic acid after a single administration in rats.
Topics: Animals; Antioxidants; Blood Pressure; Hypertension; Male; Obesity; Rats; Rats, Wistar; Thioctic Aci | 2016 |
Alpha lipoic acid supplementation attenuates reactive oxygen species in hypothalamic paraventricular nucleus and sympathoexcitation in high salt-induced hypertension.
Topics: Animals; Antioxidants; Arterial Pressure; Hypertension; Kidney; Male; Paraventricular Hypothalamic N | 2016 |
Cardioprotective effects of lipoic acid, quercetin and resveratrol on oxidative stress related to thyroid hormone alterations in long-term obesity.
Topics: Animals; Anti-Obesity Agents; Antihypertensive Agents; Antioxidants; Biomarkers; Cardiotonic Agents; | 2016 |
Oxidative stress increases the risk of pancreatic β cell damage in chronic renal hypertensive rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti | 2016 |
Inhibitory effects of alpha-lipoic acid on oxidative stress in the rostral ventrolateral medulla in rats with salt-induced hypertension.
Topics: Animals; Antioxidants; Blood Pressure; Diet; Disease Models, Animal; Hypertension; Male; Medulla Obl | 2017 |
A fatal mitochondrial disease is associated with defective NFU1 function in the maturation of a subset of mitochondrial Fe-S proteins.
Topics: Amino Acid Oxidoreductases; Carrier Proteins; Chromosomes, Human, Pair 2; Female; HeLa Cells; Homozy | 2011 |
Effects of lipoic acid in an experimentally induced hypertensive and diabetic rat model.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Hypertensi | 2013 |
Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production.
Topics: Animals; Antioxidants; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Glucose; Glycat | 2003 |
NAD(P)H oxidase activation by angiotensin II is dependent on p42/44 ERK-MAPK pathway activation in rat's vascular smooth muscle cells.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Aorta; Blood Pressure; Disease Model | 2003 |
Salt-induced hypertension in WKY rats: prevention by alpha-lipoic acid supplementation.
Topics: Aldehydes; Animals; Antioxidants; Blood Pressure; Body Weight; Calcium; Cytosol; Dietary Supplements | 2003 |
Lipoic acid attenuates hypertension and improves insulin sensitivity, kallikrein activity and nitrite levels in high fructose-fed rats.
Topics: Animals; Biological Transport; Blood Glucose; Blood Pressure; Calcium-Transporting ATPases; Creatine | 2004 |
Insulin, AGE and hypertension.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Type 2; Glycation End Products, Advanced; H | 2005 |
Dietary lipoic acid supplementation attenuates hypertension in Dahl salt sensitive rats.
Topics: Aldehydes; Animals; Antioxidants; Blood Glucose; Blood Platelets; Blood Pressure; Calcium; Dietary S | 2005 |
Modulation of cardiac and aortic peroxisome proliferator-activated receptor-gamma expression by oxidative stress in chronically glucose-fed rats.
Topics: Animals; Antioxidants; Aorta; Blood Pressure; Cells, Cultured; Gene Expression Regulation; Glucose; | 2006 |
Lipoic acid supplementation prevents cyclosporine-induced hypertension and nephrotoxicity in spontaneously hypertensive rats.
Topics: Animals; Antioxidants; Blood Pressure; Cyclosporine; Hypertension; Kidney Diseases; Male; Rats; Rats | 2006 |
Dietary alpha-lipoic acid supplementation lowers blood pressure in spontaneously hypertensive rats.
Topics: Aldehydes; Animals; Aorta; Blood Glucose; Blood Platelets; Blood Pressure; Calcium; Dietary Suppleme | 2000 |
Dietary lipoic acid supplementation prevents fructose-induced hypertension in rats.
Topics: Aldehydes; Animals; Aorta; Blood Glucose; Blood Pressure; Dietary Supplements; Disease Models, Anima | 2000 |
Effects of alpha-lipoic acid on deoxycorticosterone acetate-salt-induced hypertension in rats.
Topics: Animals; Aorta; Blood Pressure; Body Weight; Desoxycorticosterone; Dose-Response Relationship, Drug; | 2001 |
Prevention of hypertension, insulin resistance, and oxidative stress by alpha-lipoic acid.
Topics: Animals; Aorta; Blood Glucose; Blood Pressure; Body Weight; Glucose; Glutathione Peroxidase; Hyperte | 2002 |